Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ADIL 
Adial Pharmaceuticals Inc (ADIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ADIL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.5
1 Year Target Price $2.5
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.36% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.64M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 3 | Beta 1.08 | 52 Weeks Range 0.22 - 1.30 | Updated Date 09/15/2025 |
52 Weeks Range 0.22 - 1.30 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -88.32% | Return on Equity (TTM) -171.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1724895 | Price to Sales(TTM) - |
Enterprise Value 1724895 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.49 | Shares Outstanding 21828200 | Shares Floating 21719729 |
Shares Outstanding 21828200 | Shares Floating 21719729 | ||
Percent Insiders 2.46 | Percent Institutions 2.62 |
Upturn AI SWOT
Adial Pharmaceuticals Inc
Company Overview
History and Background
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focusing on developing therapies for diseases related to addiction. Founded in 2007, it aims to address unmet needs in the treatment of alcohol use disorder and other addictive disorders.
Core Business Areas
- Therapeutic Development: Adial's primary focus is developing AD04, its lead product candidate, for the treatment of Alcohol Use Disorder (AUD). They conduct clinical trials and seek regulatory approval for their drug candidates.
Leadership and Structure
The leadership team includes experienced professionals in the pharmaceutical and biotechnology industries. The organizational structure includes departments focused on research and development, clinical trials, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- AD04: AD04 is Adial's lead product candidate, an investigational, orally administered, selective serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder (AUD). It targets genetically predisposed individuals. There is no current market share, as it is still under development. Competitors include pharmaceutical companies offering other AUD treatments such as naltrexone and acamprosate from companies like Alkermes (ALKS) and Teva Pharmaceutical (TEVA).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on addiction treatment is characterized by significant unmet medical needs and a growing demand for effective therapies. It involves research and development, clinical trials, regulatory approval, and marketing of prescription medications.
Positioning
Adial is positioned as a company developing a genetically targeted therapy for AUD, which sets it apart from traditional treatments. Its competitive advantage lies in its personalized medicine approach.
Total Addressable Market (TAM)
The estimated TAM for AUD treatments is substantial, potentially billions of dollars globally. Adial aims to capture a portion of this market with AD04, if approved.
Upturn SWOT Analysis
Strengths
- Targeted therapy approach for AUD
- Proprietary technology and intellectual property
- Experienced management team
- Potential for personalized medicine in addiction treatment
Weaknesses
- Reliance on a single lead product candidate (AD04)
- Limited financial resources
- Dependence on successful clinical trials and regulatory approval
- Lack of established commercial infrastructure
Opportunities
- Growing market demand for AUD treatments
- Potential for partnerships and collaborations with larger pharmaceutical companies
- Expansion into other addiction-related disorders
- Positive clinical trial results for AD04
Threats
- Regulatory hurdles and clinical trial failures
- Competition from established pharmaceutical companies
- Generic versions of existing AUD treatments
- Changes in healthcare policies and reimbursement rates
Competitors and Market Share
Key Competitors
- ALKS
- TEVA
Competitive Landscape
Adial faces stiff competition from established pharmaceutical companies with approved AUD treatments. Its advantage lies in its targeted approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and financial performance reflecting clinical trial progress, not revenue generation.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of AD04. Analyst projections are highly speculative at this stage.
Recent Initiatives: Recent initiatives likely include ongoing clinical trials for AD04 and seeking funding for operations.
Summary
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing AD04 for AUD, targeting genetically predisposed individuals. The company is pre-revenue and depends heavily on clinical trials. Success hinges on regulatory approvals and competitive pressures from giants in the AUD market. Adial's focus on targeted therapy gives them a distinct advantage. They need to be careful and manage their cashflow.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Financial news outlets
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adial Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Glen Allen, VA, United States | ||
IPO Launch date 2018-07-30 | CEO, President & Director Mr. Cary John Claiborne MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.adial.com |
Full time employees 5 | Website https://www.adial.com | ||
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.